Triple-negative breast cancer—defined by the absence of oestrogen/progesterone receptors and human epidermal growth factor receptor 2 expression—is a complex and heterogeneous type of tumour characterised by poor prognosis, aggressive behaviour and lack of effective therapeutic strategies. The identification of new biomarkers and molecular signatures is leading to development of new therapeutic strategies including immunotherapy, targeted therapy and antibody-drug conjugates (ADCs). Against a background where chemotherapy has always been considered the standard of care, evolution towards a precision medicine approach could improve TNBC clinical practice in a complex scenario, with many therapeutic options and new drugs. The aim of this review was to focus on emerging therapeutic targets and their related specific therapy, discussing available and emerging drugs, underlining differences in approval by American and European regulatory authorities and showing the future perspective in the large number of ongoing clinical trials.

Capici, S., Ammoni, L., Meli, N., Cogliati, V., Pepe, F., Piazza, F., et al. (2022). Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything. CANCERS, 14(15) [10.3390/cancers14153729].

Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything

Cazzaniga, Marina Elena
2022

Abstract

Triple-negative breast cancer—defined by the absence of oestrogen/progesterone receptors and human epidermal growth factor receptor 2 expression—is a complex and heterogeneous type of tumour characterised by poor prognosis, aggressive behaviour and lack of effective therapeutic strategies. The identification of new biomarkers and molecular signatures is leading to development of new therapeutic strategies including immunotherapy, targeted therapy and antibody-drug conjugates (ADCs). Against a background where chemotherapy has always been considered the standard of care, evolution towards a precision medicine approach could improve TNBC clinical practice in a complex scenario, with many therapeutic options and new drugs. The aim of this review was to focus on emerging therapeutic targets and their related specific therapy, discussing available and emerging drugs, underlining differences in approval by American and European regulatory authorities and showing the future perspective in the large number of ongoing clinical trials.
Articolo in rivista - Review Essay
androgen receptor; metronomic; PI3K/AKT/mTOR; TNBC;
English
31-lug-2022
2022
14
15
3729
open
Capici, S., Ammoni, L., Meli, N., Cogliati, V., Pepe, F., Piazza, F., et al. (2022). Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything. CANCERS, 14(15) [10.3390/cancers14153729].
File in questo prodotto:
File Dimensione Formato  
Capici-2022-Cancers-VoR.pdf

accesso aperto

Descrizione: Review
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 707.03 kB
Formato Adobe PDF
707.03 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/402048
Citazioni
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 6
Social impact